These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22906906)

  • 1. Genetic considerations.
    Price MJ
    Adv Cardiol; 2012; 47():100-13. PubMed ID: 22906906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
    Tantry US; Jeong YH; Navarese EP; Kubica J; Gurbel PA
    Expert Rev Cardiovasc Ther; 2013 Apr; 11(4):447-62. PubMed ID: 23570358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
    Roberts JD; Wells GA; Le May MR; Labinaz M; Glover C; Froeschl M; Dick A; Marquis JF; O'Brien E; Goncalves S; Druce I; Stewart A; Gollob MH; So DY
    Lancet; 2012 May; 379(9827):1705-11. PubMed ID: 22464343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
    Sorich MJ; Vitry A; Ward MB; Horowitz JD; McKinnon RA
    J Thromb Haemost; 2010 Aug; 8(8):1678-84. PubMed ID: 20492467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiplatelet therapy in coronary heart disease. Some problems and achivements].
    Gratsianskiĭ NA
    Kardiologiia; 2010; 50(6):4-21. PubMed ID: 20659022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel.
    Tello-Montoliu A; Tomasello SD; Angiolillo DJ
    Adv Cardiol; 2012; 47():39-63. PubMed ID: 22906902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
    Price MJ; Tantry US; Gurbel PA
    Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic variability in the efficacy of clopidogrel].
    Kristensen KE; Rasmussen HB; Hansen PR
    Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.
    Bonello L; Camoin-Jau L; Mancini J; Bessereau J; Grosdidier C; Alessi MC; Ostorero M; Dignat-George F; Paganelli F
    Thromb Res; 2012 Jul; 130(1):70-4. PubMed ID: 22285300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of phenotypic and genetic testing in managing clopidogrel therapy.
    Chan NC; Eikelboom JW; Ginsberg JS; Lauw MN; Vanassche T; Weitz JI; Hirsh J
    Blood; 2014 Jul; 124(5):689-99. PubMed ID: 24951432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
    Rai M; Seip RL; Gupta A; McKay RG; Hirst J; Thompson PD; Ruaño G
    Conn Med; 2012 May; 76(5):267-72. PubMed ID: 22685981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.